BEYOND THE ANTIBIOTIC: NEW TOOLS TO CONTROL DRUG RESISTANCE IN THE POST-ANTIBIOTIC ERA

Abstract

Antimicrobial resistance (AMR) has become one of the defining public-health challenges of the twenty-first century, and the near-total absence of genuinely novel antibiotic classes over the past three decades has forced the field to look beyond the conventional small-molecule antibiotic for solutions. This review surveys the emerging toolbox of technologies now being developed to detect, reverse, circumvent, and prevent drug resistance. Forecasts from the Global Research on Antimicrobial Resistance Project project 39 million deaths directly attributable to bacterial AMR between 2025 and 2050, a burden that conventional pipelines alone cannot address. We examine seven principal categories of new tool: engineered antimicrobial peptides; bacteriophage therapy and engineered phages; CRISPR-Cas systems repurposed as sequence-specific antimicrobials and resistance-reversal agents; nanotechnology-based delivery and intrinsically antimicrobial nanomaterials; anti-virulence and quorum-sensing interference strategies; anti-plasmid and plasmid-curing approaches; and prevention-oriented platforms including vaccines, monoclonal antibodies, and artificial-intelligence-guided stewardship and drug discovery. For each, we describe the mechanistic rationale, summarise the most recent preclinical and clinical evidence, and assess the translational barriers that stand between promising laboratory results and routine clinical use. We argue that no single tool will replace the antibiotic; rather, the future of infection control lies in a diversified, combination-based, and precision-guided portfolio in which direct-acting biologicals, resistance-reversal agents, and prevention technologies are deployed in a coordinated manner. Four diagrams and three tables integrate the quantitative and mechanistic evidence discussed throughout.